Fresenius Medical Care's U.S. Volume Growth Is Unlikely to Reassure Investors -- Market Talk

Dow Jones

2025/02/25

1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

February 25, 2025 05:27 ET (10:27 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514061842"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514061842\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2514061842?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 18:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514061842","market":"other","top_or_hot":-1,"title":"Fresenius Medical Care's U.S. Volume Growth Is Unlikely to Reassure Investors -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 05:27 ET (10:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fresenius Medical Care's U.S. Volume Growth Is Unlikely to Reassure Investors -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFresenius Medical Care's U.S. Volume Growth Is Unlikely to Reassure Investors -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-02-25 18:27</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 25, 2025 05:27 ET (10:27 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4211","symbol_name":"區域性銀行","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514061842","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514061842","pubTimestamp":1740479220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4211":"区域性银行","BK4196":"保健护理服务","ISBC":"投资者银行","FMS":"费森尤斯医疗"},"translate_title":"费森尤斯医疗在美国的销量增长不太可能让投资者放心——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISBC":1,"FMS":0.9},"content_text":"1027 GMT - Fresenius Medical Care's U.S. volume growth is unlikely to reassure investors on its long-term growth outlook, UBS analysts say in a note. The German dialysis company's earnings beat in 4Q and solid outlook builds on a track record of delivery under this management, but is somewhat offset by subdued U.S. volume growth with its relatively modest 2025 forecast, the analysts say. For 2025, Fresenius Medical Care is guiding for revenue growth of a low-single-digit percentage and operating income growth at a high teens to high twenties percentage rate, both at constant currencies and excluding special items. Shares rise 0.65% to 44.90 euros. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 25, 2025 05:27 ET (10:27 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}